Form 13-F position report

INDAPTUS THERAPEUTICS INC

Reported by MORGAN STANLEY

INDP CUSIP 45339J204 Manager CIK 0000895421

Reported 8,936 shares, up 6,239 (231.3%) from the prior quarter.

Reported value 446.1%; share count 231.3% vs. the prior quarter.

Added
% of reported 13F value < 0.01% This manager · Q2 2026
Shares 8,936 Quarter-end amount reported
Reported value $26,808 Fair value at quarter end
Consecutive quarters held 2 Through Q2 2026

Reported position value by quarter

Reported position value by quarter

Each bar is a Form 13-F quarter-end snapshot. It does not show trades made within the quarter.

Reported position value by quarter
Date Holding Value
2021-12-31 2000
2022-03-31 0
2022-06-30 0
2022-09-30 0
2022-12-31 767
2023-03-31 1533
2023-06-30 1583
2023-09-30 2835
2023-12-31 1555
2024-03-31 1981
2024-06-30 1874
2024-09-30 1097
2024-12-31 744
2025-03-31 486
2025-06-30 0
2026-03-31 4909
2026-06-30 26808
2026-09-30 2905

Quarterly position history

How this manager's reported quarter-end position changed over time.

18 quarters
Quarterly reported position history for INDAPTUS THERAPEUTICS INC held by MORGAN STANLEY.
Quarter Activity Shares Change % of reported 13F Reported value Filed Source filing
Q3 2026 Reduced 1,263 -7,673 (-85.9%) < 0.01% $2,905 2026-11-13
Q2 2026 Added 8,936 +6,239 (231.3%) < 0.01% $26,808 2026-08-13
Q1 2026 New 2,697 +2,697 (0.0%) < 0.01% $4,909 2026-05-15
Q2 2025 Reduced 0 -884 (-100.0%) 0 $0 2025-08-15
Q1 2025 Unchanged 884 0 (0.0%) < 0.01% $486 2025-05-15
Q4 2024 Unchanged 884 0 (0.0%) < 0.01% $744 2025-02-14
Q3 2024 Unchanged 884 0 (0.0%) < 0.01% $1,097 2024-11-14
Q2 2024 Unchanged 884 0 (0.0%) < 0.01% $1,874 2024-08-14
Q1 2024 Unchanged 884 0 (0.0%) < 0.01% $1,981 2024-05-15
Q4 2023 Reduced 884 -145 (-14.1%) < 0.01% $1,555 2024-02-13
Q3 2023 Added 1,029 +200 (24.1%) < 0.01% $2,835 2023-11-15
Q2 2023 Unchanged 829 0 (0.0%) < 0.01% $1,583 2023-08-14
Q1 2023 Added 829 +300 (56.7%) < 0.01% $1,533 2023-05-15
Q4 2022 Added 529 +352 (198.9%) < 0.01% $767 2023-02-14
Q3 2022 Unchanged 177 0 (0.0%) 0 $0 2022-11-14
Q2 2022 Added 177 +172 (3440.0%) 0 $0 2022-08-15
Q1 2022 Reduced 5 -360 (-98.6%) 0 $0 2022-05-13
Q4 2021 Unchanged 365 0 (0.0%) < 0.01% $2,000 2022-02-14
Five years are shown. A free account unlocks the complete reported history. Unlock full history

Who else reported the position

11 managers reported INDAPTUS THERAPEUTICS INC for Q2 2026.

Managers reporting INDAPTUS THERAPEUTICS INC in Q2 2026.
Manager Activity Shares Change % of reported 13F Reported value Tenure
HRT FINANCIAL LP New 206,077 +206,077 < 0.01% $618,000 1 qtr
GEODE CAPITAL MANAGEMENT LLC Added 56,470 +29,463 < 0.01% $169,410 2 qtrs
JANE STREET GROUP LLC New 53,811 +53,811 < 0.01% $161,433 1 qtr
VANGUARD CAPITAL MANAGEMENT LLC New 33,652 +33,652 < 0.01% $100,956 1 qtr
VANGUARD FIDUCIARY TRUST CO New 13,967 +13,967 < 0.01% $41,901 1 qtr
MILLENNIUM MANAGEMENT LLC New 11,586 +11,586 < 0.01% $34,758 1 qtr
MORGAN STANLEY This report Added 8,936 +6,239 < 0.01% $26,808 2 qtrs
UBS Group AG New 478 +478 < 0.01% $1,434 4 qtrs
SBI Securities Co Ltd Unchanged 17 0 < 0.01% $51 5 qtrs
CITADEL ADVISORS LLC Reduced 0 -39,018 0 $0 2 qtrs
Premium adds each manager's conviction percentile across reporting peers.
Filing details and methodology As reported
Report period
June 30, 2026
Filed
August 13, 2026
Filing type
13F-HR
Position type
COM NEW

Voting authority reported

Sole
8,936
Shared
0
None
0

“None” means the manager reported no voting authority for those shares on non-routine matters. It does not disclose why and is not evidence of securities lending.

Form 13-F is a delayed quarter-end snapshot of disclosed long Section 13(f) securities. It can be filed up to 45 days after quarter end, excludes short positions and most non-U.S. securities, and does not reveal intra-quarter trading. For options, reported shares and value describe the underlying-share exposure; strike, expiry, premium, and written positions are not disclosed.